Originally published as JCO Early Release 10.1200/JCO.2004.11.035 on October 13 2004

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by King, D. M. Articles by Sondel, P. Search for Related Content PubMed PubMed Citation Articles by King, D. M. Articles by Sondel, P. Related Articles Related Editorial

Phase I Clinical Trial of the Immunocytokine EMD 273063 in Melanoma Patients

From the University of Wisconsin, Madison, WI; Departments of Medicine, Human Oncology, Surgery, Pathology, Biostatistics, Pediatrics, and Genetics, Ohio State University, Columbus, OH; The Scripps Research Institute, La Jolla CA; and EMD-Lexigen Research Center, Billerica, MA

Address reprint requests to Mark R. Albertini MD, 600 Highland Avenue, K4/414 CSC, Madison, WI 53792; e-mail: mralbert{at}facstaff.wisc.edu

PURPOSE: To evaluate the safety, toxicity, in vivo immunologic activation, and maximum-tolerated dose (MTD) of EMD 273063 (hu14.18-IL-2) in patients with metastatic melanoma.

PATIENTS AND METHODS: Thirty-three patients were treated with EMD 273063, a humanized anti-GD2 monoclonal antibody (mAb) linked to interleukin-2 (IL-2). EMD 273063 was given as a 4-hour intravenous infusion on days 1, 2, and 3 of week 1. Patients with stabilization or regression of disease could receive a second course of treatment at week 5. Dose levels evaluated were 0.8, 1.6, 3.2, 4.8, 6.0, and 7.5 mg/m²/d.

RESULTS: Nineteen of 33 patients completed course 1 with stable disease and went on to receive course 2. Eight patients had stable disease on completion of course 2. Grade 3 adverse events included hypophosphatemia (11 patients), hyperglycemia (three patients), hypotension (two patients), thrombocytopenia (one patient), hypoxia (three patients), elevated hepatic transaminases (two patients), and hyperbilirubinemia (one patient). Opioids were required for treatment-associated arthralgias and/or myalgias during 17 of 52 treatment courses. No grade 4 adverse events were observed. Dose-limiting toxicities at the MTD included hypoxia, hypotension, and elevations in AST/ALT. Grade 3 toxicities were anticipated based on prior studies of IL-2 or anti-GD2 mAbs, and all resolved. Immune activation was induced, as measured by lymphocytosis, increased peripheral-blood natural killer activity, and cell numbers, and increased serum levels of the soluble alpha chain of the IL-2 receptor complex.

CONCLUSION: Treatment with the immunocytokine EMD 273063 induced immune activation and was associated with reversible clinical toxicities at the MTD of 7.5 mg/m²/d in melanoma patients.

Supported by grant Nos. CA32685, CA14520, CA87025, CA81403, and RR03186 from the National Institutes of Health and a grant from the Midwest Athletes for Childhood Cancer Fund. Partial personnel support was provided by EMD for data management required by EMD for this study, which was beyond the clinical research and data monitoring required for this National Cancer Institute–supported study.

Work previously presented in part at the 35th Annual Meeting of the American Society of Clinical Oncology, Atlanta, GA, May 15-18, 1999; the 36th Annual Meeting of the American Society of Clinical Oncology, New Orleans, LA, May 20-23, 2000; the 38th Annual Meeting of the American Society of Clinical Oncology, Orlando, FL, May 18-21, 2002; American Association for Cancer Research Annual Meeting, Washington DC, July 11-15, 2003; and Society for Biologic Therapy Annual Meetings, Bethesda, MD, November 8-10, 2001, and San Diego, CA, November 7-9, 2002.

Authors' disclosures of potential conflicts of interest are found at the end of this article.

Related Editorial

• T-Cell Chauvinists Versus Antibody Advocates—Can't We All Just Get Along?
  Paul B. Chapman
  JCO 2004 22: 4446-4448 [Full Text]

This article has been cited by other articles:

				H. Singh, L. M. Serrano, T. Pfeiffer, S. Olivares, G. McNamara, D. D. Smith, Z. Al-Kadhimi, S. J. Forman, S. D. Gillies, M. C. Jensen, et al. Combining Adoptive Cellular and Immunocytokine Therapies to Improve Treatment of B-Lineage Malignancy Cancer Res., March 15, 2007; 67(6): 2872 - 2880. [Abstract] [Full Text] [PDF]

				Y. Zeng, N. Huebener, S. Fest, S. Weixler, U. Schroeder, G. Gaedicke, R. Xiang, A. Schramm, A. Eggert, R. A. Reisfeld, et al. Fractalkine (CX3CL1)- and Interleukin-2-Enriched Neuroblastoma Microenvironment Induces Eradication of Metastases Mediated by T Cells and Natural Killer Cells Cancer Res., March 1, 2007; 67(5): 2331 - 2338. [Abstract] [Full Text] [PDF]

				W. W. Overwijk, K. E. de Visser, F. H. Tirion, L. A. de Jong, T. W. H. Pols, Y. U. van der Velden, J. G. van den Boorn, A. M. Keller, W. A. Buurman, M. R. Theoret, et al. Immunological and Antitumor Effects of IL-23 as a Cancer Vaccine Adjuvant J. Immunol., May 1, 2006; 176(9): 5213 - 5222. [Abstract] [Full Text] [PDF]

				G. Helguera, J. A. Rodriguez, and M. L. Penichet Cytokines fused to antibodies and their combinations as therapeutic agents against different peritoneal HER2/neu expressing tumors. Mol. Cancer Ther., April 1, 2006; 5(4): 1029 - 1040. [Abstract] [Full Text] [PDF]

				K. L. Osenga, J. A. Hank, M. R. Albertini, J. Gan, A. G. Sternberg, J. Eickhoff, R. C. Seeger, K. K. Matthay, C. P. Reynolds, C. Twist, et al. A Phase I Clinical Trial of the hu14.18-IL2 (EMD 273063) as a Treatment for Children with Refractory or Recurrent Neuroblastoma and Melanoma: a Study of the Children's Oncology Group. Clin. Cancer Res., March 15, 2006; 12(6): 1750 - 1759. [Abstract] [Full Text] [PDF]

				M. Otto, R. C. Barfield, W. J. Martin, R. Iyengar, W. Leung, T. Leimig, S. Chaleff, S. D. Gillies, and R. Handgretinger Combination Immunotherapy with Clinical-Scale Enriched Human {gamma}{delta} T cells, hu14.18 Antibody, and the Immunocytokine Fc-IL7 in Disseminated Neuroblastoma Clin. Cancer Res., December 1, 2005; 11(23): 8486 - 8491. [Abstract] [Full Text] [PDF]

				D. G. McNeel, J. Eickhoff, F. T. Lee, D. M. King, D. Alberti, J. P. Thomas, A. Friedl, J. Kolesar, R. Marnocha, J. Volkman, et al. Phase I Trial of a Monoclonal Antibody Specific for {alpha}v{beta}3 Integrin (MEDI-522) in Patients with Advanced Malignancies, Including an Assessment of Effect on Tumor Perfusion Clin. Cancer Res., November 1, 2005; 11(21): 7851 - 7860. [Abstract] [Full Text] [PDF]

				G. Giaccone, C. Debruyne, E. Felip, P. B. Chapman, S. C. Grant, M. Millward, L. Thiberville, G. D'addario, C. Coens, L. S. Rome, et al. Phase III Study of Adjuvant Vaccination With Bec2/Bacille Calmette-Guerin in Responding Patients With Limited-Disease Small-Cell Lung Cancer (European Organisation for Research and Treatment of Cancer 08971-08971B; Silva Study) J. Clin. Oncol., October 1, 2005; 23(28): 6854 - 6864. [Abstract] [Full Text] [PDF]

				S. D. Gillies, Y. Lan, S. Williams, F. Carr, S. Forman, A. Raubitschek, and K.-M. Lo An anti-CD20-IL-2 immunocytokine is highly efficacious in a SCID mouse model of established human B lymphoma Blood, May 15, 2005; 105(10): 3972 - 3978. [Abstract] [Full Text] [PDF]

				P. B. Chapman T-Cell Chauvinists Versus Antibody Advocates--Can't We All Just Get Along? J. Clin. Oncol., November 15, 2004; 22(22): 4446 - 4448. [Full Text] [PDF]